Evidence map›Paper›PMID 36602034›Full record

ArticlePediatric blood & cancer2023

Thromboembolic toxicity observed with concurrent trametinib and lenalidomide therapy.

Priya P Chan, Ashley Sabus, Molly S Hemenway, Kathryn C Chatfield, Christina J White, David M Mirsky, Nicholas K Foreman, Nathan A Dahl

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric blood & cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Priya P ChanDepartment of Pediatrics, University of Utah, Salt Lake City, Utah, USA.ORCID 0000-0002-2061-8823
Ashley SabusDepartment of Pharmacy, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0002-1509-931X
Molly S HemenwayDepartment of Pediatrics, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Kathryn C ChatfieldDepartment of Pediatrics, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Christina J WhiteDepartment of Radiology, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
David M MirskyDepartment of Radiology, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Nicholas K ForemanDepartment of Pediatrics, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Nathan A DahlDepartment of Pediatrics, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

Funding

CDK9-mediated processive transcription in H3K27M+ diffuse intrinsic pontine gliomaK08NS121592 · NINDS · UNIVERSITY OF COLORADO DENVER · PI DAHL, NATHAN A · 2021 to 2025
$949k
NINDS NIH HHS K08 NS121592
6 · The paper itself

Abstract

The event-free survival of pediatric low-grade gliomas is poor, and patients often require multiple treatment strategies. While MEK and RAF inhibitors are efficacious in early-phase trials, not all patients respond, and many experience progression following completion of therapy. Evaluating combination therapies that may enhance efficacy or prolong disease stabilization is warranted. We report our institutional experience using concurrent trametinib and lenalidomide in the treatment of primary pediatric central and peripheral nervous system tumors. Two of four patients using this combination therapy experienced severe thromboembolic events, necessitating discontinuation of therapy. This combination requires further investigation, and we urge caution if used.

Indexed as

PyridonesPyrimidinonesAntineoplastic Combined Chemotherapy ProtocolsChildHumansLenalidomideProto-Oncogene Proteins B-rafLenalidomideProto-Oncogene Proteins B-rafPyridonesPyrimidinonestrametiniblenalidomidethromboembolic toxicitytrametinib

Identifiers

PMID36602034
PMCPMC10519171

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.